Initial treatment of pediatric MS or clinically isolated syndrome (CIS) with newer disease-modifying therapies (DMTs) is associated with better control of disease activity compared with treatment with injectables, researchers have reported.
Initial treatment of pediatric MS or clinically isolated syndrome (CIS) with newer disease-modifying therapies (DMTs) is associated with better control of disease activity compared with treatment with injectables, researchers have reported.